We offer education, events and other related content to give you a better understanding of the Non-muscle-invasive Bladder Cancer guidelines.
This course compiles the most recent clinical guidelines edited by the EAU in relation to Non-muscle Invasive Bladder Cancer. The Non-muscle Invasive Bladder Cancer course is divided into 3 learning units. Each Learning Unit consists of multiple choice questions that you can answer by navigating to the corresponding chapter of the Non-muscle Invasive Bladder Cancer guideline. The questions are offered for self-assessment of your knowledge of the EAU Guidelines on Non-muscle Invasive Bladder Cancer.
Generally speaking, while NMIBCs have a more favourable prognosis compared to their MI counterpart, they are not the same and seem to behave differently (i.e. some are relatively indolent, others have aggressive features). In this episode, Prof. Paolo Gontero (IT) explains why this is the case.
Epidemiology, staging and diagnosis
Bladder cancer (BC) is the 7th most commonly diagnosed cancer in males. Bladder cancer incidence and mortality rates vary across countries. Approximately 75% of patients with BC are non-muscle-invasive bladder carcinomas (NMIBC).
Review the EAU Guidelines on the risk stratification and disease management of NMIBC with this Cheat Sheet.